Clearmind Medicine EBITDA 2023-2024 | CMND

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Clearmind Medicine ebitda from 2023 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Clearmind Medicine ebitda from 2023 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$88.3B
Takeda Pharmaceutical (TAK)	$46.6B
Merck (MKGAF)	$23B
Astellas Pharma (ALPMY)	$21.6B
Sandoz Group AG (SDZNY)	$18.1B
Summit Therapeutics (SMMT)	$16.5B
United Therapeutics (UTHR)	$15.9B
Shionogi (SGIOY)	$13.3B
Neurocrine Biosciences (NBIX)	$11.7B
Catalent (CTLT)	$10.9B
Orion OYJ (ORINY)	$7.7B
Revolution Medicines (RVMD)	$7.3B
Jazz Pharmaceuticals (JAZZ)	$6.8B
Ionis Pharmaceuticals (IONS)	$6B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$4.6B
Corcept Therapeutics (CORT)	$4.5B
Crinetics Pharmaceuticals (CRNX)	$4B
Dyne Therapeutics (DYN)	$3.5B
PTC Therapeutics (PTCT)	$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Arrowhead Pharmaceuticals (ARWR)	$2.4B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Recursion Pharmaceuticals (RXRX)	$2B
Soleno Therapeutics (SLNO)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
Xencor (XNCR)	$1.6B
Harrow (HROW)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Cassava Sciences (SAVA)	$1.5B